ClinicalTrials.gg
CompletedNCT01655511Updated Sep 27, 2012

Safety And Pharmacokinetic Assessment Of Orally Administered Tafamidis In Healthy Volunteers

A Phase 1 interventional study of Tafamidis and Tafamidis in TTR Cardiomyopathy, sponsored by Pfizer. Completed at 1 site in Singapore. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-09-27.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Study summary

This study in healthy male and female volunteers will investigate the safety and tolerability of three increasing oral doses of tafamidis

02

Conditions studied

  • TTR Cardiomyopathy

Keywords

  • Pharmacokinetic
  • pharmacodynamic
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, males or females, 21 to 55 years old.
  • (BMI) of 17.5 to 30.5 kg/m2.

Exclusion criteria

Exclusion Criteria:

Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).

Condition affecting drug absorption. Blood pressure or abnormalities. Recent treatment with an , prescription, or non-prescription drug

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Period 1

    240 mg tafamidis arm

    Drug: Tafamidis

  • Experimental
    Period 2

    480 mg arm

    Drug: Tafamidis

  • Experimental
    Period 3

    TBD dose

    Drug: Tafamidis

Interventions

  • 240 mg, solution, single dose

  • 480 mg, solution, single dose

  • TBD dose will be a single dose if \< 720 mg or a loading dose followed by additional dose if \> 720 mg.

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of orally administered tafamidis in healthy volunteers at escalating doses >120 mg. Safety assessments will include spontaneous reporting of adverse events, concomitant medications, physical examination,

    Time frame: Day 0 and Day 6

  2. vital signs, ECGs, and clinical laboratory tests.

    Time frame: Day 0 and Day 6

Secondary outcomes

  1. Cmax - Maximum Observed Plasma Concentration (Cmax)

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs

  2. tmax - Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs

  3. AUC0-24 - AreArea under the Concentration-Time Curve (AUC)

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs

  4. AUClast - Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs

  5. AUCinf - Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs

  6. t½ - Plasma Decay Half-Life (t1/2)

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hrs

  7. Transthyretin blood concentration in mg/dL

    Time frame: Days 0,1,2,3,4,5,6

  8. Transthyretin stabilization (%)

    Time frame: Days 0,1,2,3,4,5,6

07

Study locations

1 site
  • Pfizer Investigational Site
    Singapore, 188770, Singapore
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2012
First posted
Aug 2, 2012
Start
Jul 2012
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Last update
Sep 27, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01655511
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 2, 2012
Start date
Jul 2012
Primary completion
Sep 2012
Completion
Sep 2012
Last update
Sep 27, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tafamidis

Start the discussion